T1	Outcomes 0 42	Subcutaneous versus intravenous bortezomib
T2	Outcomes 206 218	subcutaneous
T3	Outcomes 226 248	intravenous bortezomib
T4	Outcomes 728 742	Adverse events
T5	Outcomes 866 912	Rates of grade 2 or more peripheral neuropathy
T6	Outcomes 1040 1062	Overall response rates
T7	Outcomes 1145 1246	International Staging System stage III disease, renal impairment or adverse cytogenetic abnormalities
T8	Outcomes 1450 1458	myeloma.
T9	Outcomes 1474 1483	tolerance
T10	Outcomes 1504 1512	response
